Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Avenue Therapeutics

15/11/2024 14:06

* Avenue Therapeutics Inc  ATXI.OQ  reported a quarterly
adjusted
loss of $1.92​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of $4.50.  The lone analyst forecast for the quarter was
for a loss of 94 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Avenue Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.92​.
    * The company reported a quarterly loss of $3.08 million.
    * Avenue Therapeutics Inc shares had fallen by 24.5% this
quarter and lost 84.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Avenue
Therapeutics Inc is 12.00 
This summary was machine generated from LSEG data November 15 at
02:06 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.94          -1.92          Missed
 Jun. 30 2024      -1.05          -6.43          Missed
 Mar. 31 2024      -9.00          -15.40         Missed
 Dec. 31 2023      -7.50          4.50           Beat